NASDAQ:ZEAL Zealand Pharma A/S (ZEAL) Stock Price, News & Analysis → AI Cracks Open Largest Untapped Energy Reserve on Earth (From Banyan Hill Publishing) (Ad) Free ZEAL Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$17.59▼$17.5950-Day Range$16.54▼$19.2052-Week Range$9.93▼$32.94VolumeN/AAverage Volume4,965 shsMarket Capitalization$818.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Zealand Pharma A/S alerts: Email Address Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit About Zealand Pharma A/S Stock (NASDAQ:ZEAL)Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.Read More Ad Banyan Hill PublishingAI Cracks Open Largest Untapped Energy Reserve on EarthThis orb represents the largest untapped energy source in the world… And although this energy resource is unknown by 99% of the public… It makes gas, coal, oil, wind, hydropower, solar, fusion… ]click here to watch a free presentation where I reveal all the details of this lucrative opportunit ZEAL Stock News HeadlinesMarch 17, 2024 | businessinsider.comWeight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last yearMarch 15, 2024 | msn.comWhat is amycretin? The new weight-loss pill that’s ‘twice as effective’ as OzempicMarch 19, 2024 | The Bull Report (Ad)The AI Bottleneck No One is Talking AboutRenewable energy is growing at an impressive speed - but not fast enough. This could be one of the greatest periods for the nuclear industry ever.March 14, 2024 | yahoo.comFactbox-Madrigal's drug wins first US approval for fatty liver disease NASH as rivals circleMarch 13, 2024 | globenewswire.comNew Employee Elected Directors to the Board of Zealand Pharma A/SMarch 13, 2024 | msn.comWho benefits from direct-to-consumer pharmaceutical advertising?March 8, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMarch 5, 2024 | globenewswire.comTransactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsMarch 19, 2024 | InvestorPlace (Ad)They said crypto was dead. It went up 100X.Bitcoin’s haters are out again. Despite the price doubling in the last six months alone… That hasn’t stopped the experts from piling on. Warren Buffett’s right-hand man Charlie Munger called crypto investors “idiots” in one of his last interviews. JPMorgan CEO Jamie Dimon, recently called Bitcoin a “pet rock” and “a hyped-up fraud.” But when it comes to cryptos, these are exactly the people you shouldn’t listen to. They’ve predicted crypto’s demise for years.March 5, 2024 | globenewswire.comZealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee WarrantsMarch 1, 2024 | globenewswire.comZealand Pharma to Participate in TD Cowen's 44th Annual Health Care ConferenceFebruary 27, 2024 | finance.yahoo.comZealand Pharma A/S (ZEAL.CO)February 27, 2024 | globenewswire.comZealand Pharma Announces Financial Results for the Full Year 2023February 26, 2024 | cnbc.comEuropean markets close lower as investors await inflation data; Zealand Pharma up 35%February 26, 2024 | uk.investing.comZealand Pharma stock soars 35% on strong trial results for its weight loss treatmentFebruary 26, 2024 | msn.comThere might be a weight loss drug competitor to Ozempic — and the company's stock is soaringFebruary 26, 2024 | msn.comZealand Pharma’s Survodutide Shows Promise in Obesity Treatment: Latest Trial Results Spark Investor ExcitementFebruary 26, 2024 | globenewswire.comZealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosisFebruary 25, 2024 | msn.comZealand Pharma A (ZLDPF) Price Target Increased by 5.13% to 66.05February 20, 2024 | globenewswire.comZealand Pharma conference call on February 27 at 2pm CET (8am ET) to present full year 2023 financial resultsFebruary 19, 2024 | msn.comOut of the rabbit hole: new research shows people can change their minds about conspiracy theoriesJanuary 31, 2024 | barrons.comNew Zealand To Ban 'Forever Chemicals' In Make-upJanuary 31, 2024 | thestreet.comZealand Pharma A/SJanuary 10, 2024 | finance.yahoo.comZealand Pharma major shareholder announcement: Avoro Capital Advisors LLCJanuary 8, 2024 | finance.yahoo.comZealand Pharma announces directed issue and private placement for gross proceeds of DKK 1.45 billionJanuary 2, 2024 | finance.yahoo.comZealand Pharma to participate in the Goldman Sachs Healthcare C-Suite Unscripted Conference on January 4thDecember 23, 2023 | reuters.comUS FDA declines to approve Zealand Pharma's drug for low blood sugar in childrenSee More Headlines Receive ZEAL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zealand Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today3/18/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ZEAL CUSIPN/A CIK1674988 Webwww.zealandpharma.com Phone(458) 877-3600Fax45-8877-3898Employees355Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-161,990,000.00 Net Margins-565.44% Pretax Margin-364.34% Return on Equity-111.04% Return on Assets-56.54% Debt Debt-to-Equity Ratio0.93 Current Ratio4.79 Quick Ratio4.78 Sales & Book Value Annual Sales$46.54 million Price / Sales17.59 Cash FlowN/A Price / Cash FlowN/A Book Value$3.38 per share Price / Book5.20Miscellaneous Outstanding Shares46,538,000Free Float45,514,000Market Cap$818.60 million OptionableNot Optionable Beta1.45 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Adam Sinding Steensberg M.D. (Age 48)Pres & CEO Comp: $680.16kMr. Ivan Mourits Moller (Age 50)Chief Operating Officer Lani Pollworth MorvanInvestor Relations & Communications OfficerMr. Mads KronborgHead of Investor Relations & CommunicationMr. Ravinder ChahilSr. VP & Gen. CounselMs. Christina Sonnenborg Bredal (Age 37)Sr. VP and Global Head of People & Organization Ms. Hanne Heidenheim Bak (Age 69)Sr. Project Director, R&D Operations Mang. and Employee Representative Director Dr. Jens Damsgaard Mikkelsen M.D.Head of Molecular PharmacologyDr. Danilo VergeHead of Global Medical AffairsDr. David M. Kendall M.D. (Age 60)Chief Medical Officer More ExecutivesKey CompetitorsEvolusNASDAQ:EOLSWave Life SciencesNASDAQ:WVETyra BiosciencesNASDAQ:TYRAARS PharmaceuticalsNASDAQ:SPRYAcelyrinNASDAQ:SLRNView All Competitors ZEAL Stock Analysis - Frequently Asked Questions Should I buy or sell Zealand Pharma A/S stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zealand Pharma A/S in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ZEAL shares. View ZEAL analyst ratings or view top-rated stocks. How were Zealand Pharma A/S's earnings last quarter? Zealand Pharma A/S (NASDAQ:ZEAL) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($4.61) earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.31) by $1.70. The business earned $16.87 million during the quarter, compared to analyst estimates of $12.21 million. Zealand Pharma A/S had a negative net margin of 565.44% and a negative trailing twelve-month return on equity of 111.04%. During the same quarter in the previous year, the firm posted ($0.90) EPS. What other stocks do shareholders of Zealand Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zealand Pharma A/S investors own include AbbVie (ABBV), Galapagos (GLPG), Verizon Communications (VZ), Dynavax Technologies (DVAX), EyePoint Pharmaceuticals (EYPT), Progenics Pharmaceuticals (PGNX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO) and Sorrento Therapeutics (SRNE). When did Zealand Pharma A/S IPO? (ZEAL) raised $75 million in an IPO on Wednesday, August 9th 2017. The company issued 3,900,000 shares at $19.30 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers. This page (NASDAQ:ZEAL) was last updated on 3/19/2024 by MarketBeat.com Staff From Our PartnersCentral Bank Gold Heist In ProgressColonial Metals8,788% Return Predicted For THIS Crypto (already up 40% in 6 months)Paradigm PressAltcoin FRENZY Alert…Crypto 101 MediaThe AI Bottleneck No One is Talking AboutThe Bull ReportThe world’s greatest investmentPorter & CompanyMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceSHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zealand Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.